These tumor-related clinical studies have demonstrated that IL-21 can activate CD8+ T cells and NK cells (upregulating perforin and granzyme B) and induce polyclonal CTL responses, a mechanism similar to IL-21-driven alloreactive T cell activation in transplant rejection. This evidence concerns the gene CD8A and neoplasm.